Literature DB >> 16274669

Cystathionine beta-synthase is enriched in the brains of Down's patients.

Akiko Ichinohe1, Takeshi Kanaumi, Sachio Takashima, Yasushi Enokido, Yasuo Nagai, Hideo Kimura.   

Abstract

Down's syndrome (DS) or trisomy 21 is the most common genetic cause of mental retardation, and adults with DS develop Alzheimer type of disease (AD). Cystathionine beta-synthase (CBS) is encoded on chromosome 21 and deficiency in its activity causes homocystinuria, the most common inborn error of sulfur amino acid metabolism and characterized by mental retardation and vascular disease. Here, we show that the levels of CBS in DS brains are approximately three times greater than those in the normal individuals. CBS is localized to astrocytes and those surrounding senile plaques in the brains of DS patients with AD. The over-expression of CBS may cause the developmental abnormality in cognition in DS children and that may lead to AD in DS adults.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16274669     DOI: 10.1016/j.bbrc.2005.10.118

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  49 in total

1.  Hydrogen sulfide protects the retina from light-induced degeneration by the modulation of Ca2+ influx.

Authors:  Yoshinori Mikami; Norihiro Shibuya; Yuka Kimura; Noriyuki Nagahara; Masahiro Yamada; Hideo Kimura
Journal:  J Biol Chem       Date:  2011-09-20       Impact factor: 5.157

Review 2.  Modes of physiologic H2S signaling in the brain and peripheral tissues.

Authors:  Bindu D Paul; Solomon H Snyder
Journal:  Antioxid Redox Signal       Date:  2014-05-09       Impact factor: 8.401

3.  Synthesis of Amino-ADT Provides Access to Hydrolytically Stable Amide-Coupled Hydrogen Sulfide Releasing Drug Targets.

Authors:  Matthew D Hammers; Loveprit Singh; Leticia A Montoya; Alan D Moghaddam; Michael D Pluth
Journal:  Synlett       Date:  2016       Impact factor: 2.454

Review 4.  Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter.

Authors:  John L Wallace; Rui Wang
Journal:  Nat Rev Drug Discov       Date:  2015-04-07       Impact factor: 84.694

Review 5.  Redox Signaling Mediated by Thioredoxin and Glutathione Systems in the Central Nervous System.

Authors:  Xiaoyuan Ren; Lili Zou; Xu Zhang; Vasco Branco; Jun Wang; Cristina Carvalho; Arne Holmgren; Jun Lu
Journal:  Antioxid Redox Signal       Date:  2017-05-18       Impact factor: 8.401

6.  Alterations in the Serotonin and Dopamine Pathways by Cystathionine Beta Synthase Overexpression in Murine Brain.

Authors:  J London; F K Ndiaye; L C Bui; B Souchet; F Daubigney; C Magnan; S Luquet; J Dairou; N Janel; C Rouch
Journal:  Mol Neurobiol       Date:  2018-09-20       Impact factor: 5.590

Review 7.  Hydrogen sulfide signalling in the CNS - Comparison with NO.

Authors:  Hideo Kimura
Journal:  Br J Pharmacol       Date:  2020-09-20       Impact factor: 8.739

8.  DHFR 19-bp deletion and SHMT C1420T polymorphisms and metabolite concentrations of the folate pathway in individuals with Down syndrome.

Authors:  Cristiani Cortez Mendes; Aline Maria Zanchetta de Aquino Raimundo; Luciana Dutra Oliveira; Bruna Lancia Zampieri; Gustavo Henrique Marucci; Joice Matos Biselli; Eny Maria Goloni-Bertollo; Marcos Nogueira Eberlin; Renato Haddad; Maria Francesca Riccio; Hélio Vannucchi; Valdemir Melechco Carvalho; Érika Cristina Pavarino
Journal:  Genet Test Mol Biomarkers       Date:  2013-02-19

9.  Plasma amino acids and neopterin in healthy persons with Down's syndrome.

Authors:  A W Coppus; D Fekkes; W M A Verhoeven; S Tuinier; J I M Egger; C M van Duijn
Journal:  J Neural Transm (Vienna)       Date:  2007-03-31       Impact factor: 3.575

10.  A novel mouse model for Down syndrome that harbor a single copy of human artificial chromosome (HAC) carrying a limited number of genes from human chromosome 21.

Authors:  Kenichi Miyamoto; Nobutaka Suzuki; Kosuke Sakai; Shuichi Asakawa; Tsuneko Okazaki; Jun Kudoh; Masashi Ikeno; Nobuyoshi Shimizu
Journal:  Transgenic Res       Date:  2013-11-30       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.